Lyell Immunopharma, Inc.
For the period ended Nov 4, 2026. Filed Nov 4, 2026.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Nov 4, 2026 · Filed Nov 4, 2026
Use the contents to explore the available documents and sections.
LYEL$14.86-0.9%Stored close · as of Nov 6, 2026
Contents
EX-99.1 · Statement of Operations Data:
Statement of Operations Data:
| Three Months Ended September 30, | Nine Months Ended September 30, | |||
|---|---|---|---|---|
| 2026 | 2025 | 2026 | 2025 | |
| Revenue | $3 | $15 | $9 | $30 |
| Operating expenses: | ||||
| Research and development | 40,898 | 28,172 | 117,026 | 106,476 |
| General and administrative | 9,297 | 10,687 | 28,428 | 34,519 |
| Other operating income, net | (1,897) | (1,591) | (5,552) | (648) |
| Impairment of long-lived assets | — | — | — | 1,443 |
| Total operating expenses | 48,298 | 37,268 | 139,902 | 141,790 |
| Loss from operations | (48,295) | (37,253) | (139,893) | (141,760) |
| Interest income, net | 1,905 | 3,266 | 6,283 | 10,404 |
| Other income (expense), net | 861 | (4,859) | 19,173 | (2,369) |
| Total other income (loss), net | 2,766 | (1,593) | 25,456 | 8,035 |
| Net loss | $(45,529) | $(38,846) | $(114,437) | $(133,725) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.